GLPwatch
Papers (12034)
Page 156 of 201, ranked by citation count.
- Coronary Artery Calcium Scoring Improves Allocation of the GLP-1 Receptor Agonist Semaglutide.
- Re-evaluating GLP-1 receptor agonist-associated changes in copeptin.
- Type 2 diabetes and cardiovascular disease: A metabolic overview of recent clinical trials.
- Molecular Characterization of the Effect of Glucagon-Like Peptide-1 Receptor Agonist Semaglutide in the Nephrotoxic Serum Nephritis Mouse Model.
- PRISMA-efficacy and safety of lixisenatide for type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
- Drug adherence, glycemic control, and weight reduction with subcutaneous semaglutide in real-world management of type 2 diabetes.
- No evidence that tirzepatide can worsen diabetic retinopathy.
- Efficacy and safety of oral semaglutide treatment in a Danish type 2 diabetes outpatient clinic: Real-world evidence.
- Psoriasis flare following tirzepatide initiation in a patient with plaque psoriasis in remission: A case report.
- Liraglutide Attenuates Disease Severity in Experimental Autoimmune Encephalomyelitis by Modulating Splenic T Helper Cell Subsets.
- Exploring the rates of Gastrointestinal adverse effects among five GLP-1 receptor agonists: A systematic review and Meta-Analysis of randomized controlled trials.
- Comparing the bioequivalence and safety of liraglutide in healthy Chinese subjects: an open, single-dose, randomized, repeated, two-sequence, two-cycle phase I clinical trial.
- Regulation of nanoparticle exocytosis direction via receptors transfer: A novel strategy to enhance therapeutic efficacy of semaglutide.
- Rates of, Reasons for, and Reactions to Discontinuation of GLP-1 Receptor Agonists: A Narrative Review.
- Challenges in Modelling the Cost Effectiveness of Pharmacotherapies for Obesity.
- Semaglutide and tirzepatide for obesity: A summary from the Institute for Clinical and Economic Review's New England Comparative Effectiveness Public Advisory Council.
- Morphology-driven zinc oxide biointeractive carriers with biological barrier modulating effects for pulmonary delivery of liraglutide.
- Semaglutide in patients with hidradenitis suppurativa and obesity.
- Liraglutide Modulates Zinc Release and Improves Mitochondrial Function in Insulin-Resistant Senescent Cardiomyocytes.
- Association Between Glucagon-Like Peptide-1 Receptor Agonists and Suicidality: A Systematic Review.
- Comparative efficacy of GLP-1 RA, tirzepatide and SGLT-2 inhibitors in metabolic liver disease: A network meta-analysis.
- The role of glucagon-like peptide-1 receptor agonists in cardiovascular disease prevention in type 2 diabetes mellitus: evidence from the most recent clinical trials.
- Highlights From AHA 2023-New Risk Calculator, Semaglutide and CVD, and More.
- Role of Dual GIP and GLP-1 Receptor Agonist, Tirzepatide in the Management of Weight Loss; A Systematic Review
- Comparison of trajectories of self-monitored glucose levels by hypoglycemia status over 52 weeks of treatment with insulin glargine or exenatide once weekly.
- Lixisenatide once daily significantly improves post-prandial glucose throughout the day due to diverse mechanistic effects.
- Once-Weekly Semaglutide Is an Effective Adjunct for Weight Loss in Adults without Diabetes Who Are Overweight or Obese.
- Effects of tryptophan-selective lipidated glucagon-like peptide 1 (GLP-1) peptides on the GLP-1 receptor.
- Effect of a Novel GLP-1 Analogue Ecnoglutide on the Pharmacokinetics of Rosuvastatin and Digoxin in Healthy Participants.
- Reply to the comment of Wilbrink et al. on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes: The association between remaining β-cell function and the achievement of the HbA1c target 1 year after initiation.
- Cardiometabolic Profiles of Oral and Subcutaneous Glucagon-Like Peptide-1 Receptor Mono-Agonists in Adults With Overweight or Obesity: A Systematic Review and Network Meta-Analysis.
- Association of tirzepatide and the risk of suicide in a real-world cohort.
- Evaluating semaglutide + LAI-287 (IcoSema) for the treatment of diabetes mellitus type II.
- Amylin Revisited: A 5-Year Perspective on Its Emerging Role in the Treatment of Diabesity.
- Elective semaglutide prescription enabled waitlisting and transplantation of otherwise ineligible obese renal transplant candidates.
- Glycaemic and weight effects of metabolic surgery or semaglutide in diabetes dosage for patients with type 2 diabetes.
- Cardiovascular Safety Profile of Semaglutide and Variations by Sex, Race, and Kidney Function: A Systematic Review and Meta-analysis.
- Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.
- Clinical Manifestations of Semaglutide Overdose: A Case Study.
- Acute liver injury associated with tirzepatide: An unexpected adverse event warranting clinical attention.
- Unlocking the Potential of Type 2 Diabetes Mellitus Remission.
- Use of Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study.
- Liraglutide induces enhanced suppression of food intake in mice lacking the growth hormone secretagogue receptor.
- Do GLP-1 Receptor Agonists Care if You Have Heart Failure?
- [Obesity treatment: will pharmacotherapies replace metabolic surgery in the future?]
- Detection of adverse drug reactions among ordinary users of liraglutide on the occasion of drug dispensing in the community pharmacy setting.
- Non-arteritic anterior ischaemic optic neuropathy incidence in placebo-controlled clinical trials of liraglutide or semaglutide.
- Liraglutide prevents lupus-associated diffuse alveolar hemorrhage via inhibiting lymphocyte infiltration and promoting macrophage M2 polarization.
- R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 25.
- Liraglutide for patients with non-alcoholic steatohepatitis - Authors' reply.
- <i>In vitro</i> cellular uptake and insulin secretion studies on INS-1E cells of exendin-4-loaded self-nanoemulsifying drug delivery systems.
- Integrating cardioprotective glucose-lowering medications into clinical practice.
- Initiators of Semaglutide in General Practice in New South Wales, 2020-2023: A Retrospective Cohort Study.
- Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.
- Comparative Gynecological Safety of the Dual GIP/GLP-1 Receptor Agonist Tirzepatide vs. the GLP-1 Receptor Agonist Semaglutide: A Real-World Pharmacovigilance Analysis (2022-2025).
- Is Liraglutide Associated With Myocardial Protection in ST-Elevation Myocardial Infarction?
- FABP4, marker of worse prognosis in cardiovascular disease, induces neutrophil's proatherogenic phenotype which is modulated by semaglutide.
- Effect of Peptide Drug Liraglutide Nano-Formulation Combined with Sodium-Glucose Cotransporter-2 Inhibitor on Blood Lipids in Patients with Type 2 Diabetes.
- Effects of semaglutide in patients with chronic ankle instability: evidence from a prospective cohort.
- Once-weekly glucagon-like peptide 1 receptor agonists.